ClinicalTrials.gg
RecruitingNCT07832188Updated Sep 21, 2026

A Study on the Efficacy of Dual-Carrier-Frequency Transcranial Alternating Current Stimulation Modulating the Hippocampus for the Treatment of Chronic Non-Specific Low Back Pain

An interventional study of Dual-carrier-frequency transcranial alternating current stimulation and Transcranial electrical stimulation (tES) in Chronic Pain, sponsored by Qilu Hospital of Shandong University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Qilu Hospital of Shandong University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Chronic Pain with a site in China — 14 open to participants now, 15 under way, 1 of them phase 3. Chronic Pain · China.

Planned enrollment
21st of 34
60 · median 80
Started
2026
with 3 others
No phase
21 of 43
8 open now
Primary completion
2029-09
later than 14 of 14 live
Registered
43rd of 43
by date

Among the 43 studies in Chronic Pain with a site in China, this one is the 21st largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 21 with no phase, reaches primary completion later than 14 of the 14 other live ones, and was the 43rd registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

14 of the 43 studies in Chronic Pain with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Chronic Pain with a site in China, or all of them as a file.
02

Study summary

This is a single-center, randomized, double-blind, sham-controlled trial evaluating dual-carrier-frequency transcranial alternating current stimulation targeting the hippocampus in 60 patients with chronic non-specific low back pain. Participants will be randomized into four groups: active stimulation, active stimulation with iTBS, superficial stimulation control, and sham control. All groups will receive standard rehabilitation. The intervention is 20 minutes per session, 5 sessions weekly for 2 weeks (10 sessions total).

The primary objective is to assess improvements in pain intensity (VAS) and emotional symptoms (anxiety, depression) at week 2. Exploratory objectives include examining functional connectivity changes between the hippocampus and prefrontal/sensory cortices using fMRI, MEG, and fNIRS, and correlating these with clinical improvements.

Outcomes include VAS (primary), McGill Pain Questionnaire, HAMA, HAMD, ODI, CSI, PSQI, and objective measures (brain imaging, EEG, EMG). Assessments occur at baseline (T0), post-first stimulation (T1), mid-treatment (T2), treatment end (T3), and 2-week follow-up (T4).

Linear mixed-effects models will be used for analysis with multiple comparison correction. This study aims to provide evidence for hippocampal-targeted neuromodulation in chronic non-specific low back pain.

03

Conditions studied

  • Chronic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 80 years;
  2. Meets the diagnostic criteria for non-specific low back pain as specified in the Chinese Clinical Guidelines for the Diagnosis and Treatment of Non-specific Low Back Pain (2022) ;
  3. Diagnosed with chronic non-specific low back pain within the past 3 months, or pain located between T12 and the gluteal fold for at least half of the days within the past 6 months;
  4. VAS score ≥ 3 (Visual Analogue Scale, 0-10);
  5. Mechanical pain induced by posture, activity, and movement (e.g., flexion and functional movement tasks);
  6. Voluntarily agrees to participate in this study and has signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Clear etiology of specific low back pain, such as vertebral fracture, severe spinal cord/nerve root compression symptoms (progressive neurological deficit), spinal infection, tumor, ankylosing spondylitis, etc.;
  2. Prior major lumbar surgery or implants (e.g., internal fixation, spinal cord stimulation devices, etc.), or recent (within 3 months) invasive analgesic treatments such as nerve blocks or radiofrequency ablation;
  3. to MEG or MRI, including the presence of ferromagnetic metal implants in the body (e.g., cardiac pacemakers, hearing aids, carotid artery stents, etc.), claustrophobia that precludes MEG examination, or failed MEG acquisition;
  4. History of severe cardiovascular disease, epilepsy, or other conditions that contraindicate electrical stimulation;
  5. Pregnancy or lactation;
  6. Cognitive impairment, psychiatric disorders, or other conditions that prevent understanding or compliance with the study procedures;
  7. Rheumatic diseases, connective tissue diseases, or diabetes.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    TI Group

    Interference currents of 2 kHz and 2.010 kHz are delivered through scalp electrodes to produce a 10 Hz modulation effect in the right hippocampus. The stimulation current is gradually increased from 0.5 mA to 2 mA, and electrode placement is optimized using a head model. A total of 10 sessions are administered (5 sessions per week for 2 weeks), with routine pain rehabilitation performed immediately after each session.

    Device: Dual-carrier-frequency transcranial alternating current stimulation

  • Active comparator
    TI-iTBS Group

    In addition to the parameters used in the TI group, an intermittent theta-burst stimulation (iTBS) pattern is superimposed. All other parameters, including current intensity, target region, treatment frequency, total course, and subsequent rehabilitation, are identical to those of the TI group.

    Device: Dual-carrier-frequency transcranial alternating current stimulation

  • Active comparator
    tES Group

    Cortical electrical stimulation is applied, with electrodes primarily placed over the primary somatosensory cortex (S1 region) to activate superficial cortical layers and modulate the sensorimotor network. Stimulation intensity is set within the tolerated range. Each session lasts 20 minutes, and the treatment frequency, total course, and subsequent rehabilitation are consistent with those of the previous two groups.

    Device: Transcranial electrical stimulation (tES)

  • Sham comparator
    Sham group

    Electrode placement and the operational procedures are identical to those of the TI group. However, the current output during the treatment is 0 mA, with only the onset and offset sensations of stimulation being simulated, and no effective frequency difference or envelope modulation is generated. The treatment course, frequency, and subsequent rehabilitation are the same as those of the other groups, aiming to maintain blinding without producing any neuromodulatory effects.

    Device: Dual-carrier-frequency transcranial alternating current stimulation

Interventions

  • DeviceDual-carrier-frequency transcranial alternating current stimulation

    Dual-carrier-frequency transcranial alternating current stimulation is based on the interference principle. Two pairs of carrier-frequency alternating currents with slightly different frequencies are applied to the scalp. After intracranial superposition, the nonlinear response of biological tissues generates a low-frequency envelope-modulated electric field in deep brain regions. This interference electric field oscillates periodically at the difference between the two carrier frequencies, enabling entrainment and modulation of neuronal rhythms in deep structures. This distinguishes it from conventional transcranial electrical stimulation, in which electric field intensity decays exponentially with depth, predominantly affecting superficial cortical layers and having limited efficacy in modulating deep nuclei. In terms of safety, this technique is a non-invasive stimulation method. Adverse effects are limited to mild tingling or itching at the electrode contact sites, indicating favo

    Also known as: Temporal interference (TI)

  • DeviceTranscranial electrical stimulation (tES)

    Cortical electrical stimulation is a neuromodulation technique in which electrodes are placed on the surface of the cerebral cortex or over the dura mater to deliver weak electrical currents for direct modulation of local neuronal electrical activity. By either exciting or inhibiting neuronal firing in specific cortical regions, it can regulate functional brain networks and is commonly used in studies on brain function mapping, neurorehabilitation, and pain modulation.

06

What researchers measure

Primary outcomes

  1. Visual Analogue Scale (VAS)

    A 100-mm visual analogue scale is used, with "0" indicating no pain and "10" indicating the worst possible pain; the subject marks the current pain level on the scale, and the distance (mm) from the left end is measured as the VAS score

    Time frame: Pre-enrollment (T0), immediately after the first intervention (T1), mid-intervention (T2), end of the 2-week intervention (T3), and 2-week follow-up (T4)

Secondary outcomes

  1. Ultrasound

    A high-frequency linear array ultrasound probe (≥10 MHz) is placed over the erector spinae and multifidus muscles; cross-sectional and longitudinal gray-scale images are acquired in standardized positions, and muscle thickness, cross-sectional area, and echo intensity are measured using image analysis software to assess morphological and structural changes

    Time frame: Pre-enrollment (T0), immediately after the first intervention (T1), end of the 2-week intervention (T3), and 2-week follow-up (T4)

  2. Motion Sensors

    Inertial measurement unit (IMU) sensors integrating tri-axial accelerometers, gyroscopes, and magnetometers are attached to the subject's lumbar region and bilateral lower limbs; continuous data on acceleration, angular velocity, and orientation are collected during standardized walking and trunk movement tasks, and gait parameters, trunk range of motion, and symmetry indices are calculated using dedicated algorithms

    Time frame: Pre-enrollment (T0), immediately after the first intervention (T1), end of the 2-week intervention (T3), and 2-week follow-up (T4)

  3. Central Sensitization Inventory (CSI)

    A 25-item self-administered questionnaire is used, with each item scored from 0 to 4 (never to always); the total score ranges from 0 to 100, with higher scores indicating a higher degree of central sensitization

    Time frame: Pre-enrollment (T0), immediately after the first intervention (T1), mid-intervention (T2), end of the 2-week intervention (T3), and 2-week follow-up (T4)

  4. Magnetoencephalography (MEG)

    A whole-head magnetoencephalography system is used to record spontaneous brain magnetic signals in a shielded room during the resting state; source localization algorithms are applied to reconstruct the magnetic signals from the scalp to the intracerebral source space, and spectral power and functional connectivity of the hippocampus and pain-related brain regions are assessed

    Time frame: Pre-enrollment (T0), immediately after the first intervention (T1), end of the 2-week intervention (T3), and 2-week follow-up (T4)

  5. Functional Magnetic Resonance Imaging (fMRI)

    Blood oxygen level-dependent (BOLD) functional imaging is performed using a 3.0T or higher MRI scanner; the subject remains in a resting state during scanning, and functional connectivity is assessed by measuring the temporal synchronization of low-frequency BOLD signal oscillations between brain regions, with a focus on connectivity changes between the hippocampus, prefrontal cortex, and somatosensory cortex

    Time frame: Pre-enrollment (T0),end of the 2-week intervention (T3),

  6. Functional Near-Infrared Spectroscopy (fNIRS)

    A multi-channel functional near-infrared spectroscopy system is used, with optodes placed over the scalp regions corresponding to the prefrontal cortex and sensorimotor cortex; changes in oxygenated and deoxygenated hemoglobin concentrations are monitored in real time by measuring near-infrared light attenuation, reflecting regional cerebral functional activity.

    Time frame: Pre-enrollment (T0), immediately after the first intervention (T1), end of the 2-week intervention (T3), and 2-week follow-up (T4)

  7. Surface Electromyography (sEMG)

    Surface electrodes are placed symmetrically over the bilateral erector spinae and multifidus muscle bellies; sEMG signals are recorded during standardized functional movements (e.g., trunk flexion and extension), and after amplification, filtering and root mean square (RMS) processing, time-domain and frequency-domain parameters are extracted to assess muscle activation patterns and fatigue

    Time frame: Pre-enrollment (T0), immediately after the first intervention (T1), end of the 2-week intervention (T3), and 2-week follow-up (T4)

  8. Hamilton Depression Scale (HAMD)

    The 17-item version of the Hamilton Depression Scale is administered by a trained evaluator through a structured interview; the total score ranges from 0 to 52, with higher scores indicating more severe depressive symptoms.

    Time frame: Pre-enrollment (T0), immediately after the first intervention (T1), mid-intervention (T2), end of the 2-week intervention (T3), and 2-week follow-up (T4)

  9. Hamilton Anxiety Scale (HAMA)

    The 14-item version of the Hamilton Anxiety Scale is administered by a trained evaluator through a structured interview; the total score ranges from 0 to 56, with higher scores indicating more severe anxiety symptoms.

    Time frame: Pre-enrollment (T0), immediately after the first intervention (T1), mid-intervention (T2), end of the 2-week intervention (T3), and 2-week follow-up (T4)

  10. McGill Pain Questionnaire (MPQ)

    A standardized self-administered questionnaire comprising sensory, affective, and evaluative dimensions is used; the subject selects the most appropriate pain descriptors based on personal pain experience, and the Pain Rating Index (PRI) and Present Pain Intensity (PPI) scores are calculated

    Time frame: Pre-enrollment (T0), immediately after the first intervention (T1), mid-intervention (T2), end of the 2-week intervention (T3), and 2-week follow-up (T4)

  11. Oswestry Disability Index (ODI)

    A 10-item self-administered questionnaire (covering pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and traveling) is used; each item is scored 0-5, and the sum is expressed as a percentage of the maximum possible score (0-100%), with higher percentages indicating more severe disability

    Time frame: Pre-enrollment (T0), immediately after the first intervention (T1), mid-intervention (T2), end of the 2-week intervention (T3), and 2-week follow-up (T4)

  12. Pittsburgh Sleep Quality Index (PSQI)

    A 19-item self-administered questionnaire comprising 7 component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction) is used; each component is scored 0-3, and the sum yields a global PSQI score (0-21), with a score \>5 indicating poor sleep quality

    Time frame: Pre-enrollment (T0), immediately after the first intervention (T1), mid-intervention (T2), end of the 2-week intervention (T3), and 2-week follow-up (T4)

  13. Electroencephalography (EEG)

    Scalp electroencephalography is recorded using the international 10-20 electrode placement system during both resting and task states; signals are amplified, filtered, and digitized, and power spectral density across frequency bands (δ, θ, α, β, γ) and EEG microstate features are extracted to assess changes in spontaneous neural electrical activity

    Time frame: Pre-enrollment (T0), immediately after the first intervention (T1), end of the 2-week intervention (T3), and 2-week follow-up (T4)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Luo H, Ye X, Cai HT, Wang M, Wang Y, Liu Q, Xu Y, Mao Z, Cai Y, Hong J, Zhang C, Wei P, Lu Y, Liu Q, Xu J, Yuan TF. Frequency-specific and state-dependent neural responses to brain stimulation. Mol Psychiatry. 2025 Jul;30(7):2880-2890. doi: 10.1038/s41380-025-02892-7. Epub 2025 Jan 20. PubMed 39833357 ↗
  • Esmaeilpour Z, Kronberg G, Reato D, Parra LC, Bikson M. Temporal interference stimulation targets deep brain regions by modulating neural oscillations. Brain Stimul. 2021 Jan-Feb;14(1):55-65. doi: 10.1016/j.brs.2020.11.007. Epub 2020 Nov 11. PubMed 33186778 ↗
  • Ding M, Xiang S, Zhang Y, Wei L, Weng Y, Zhang X, Ni Y, Zhang Y, Wang Q, Hou R, Du H, Chio KK, Zhang W, Wang H, Jia T, Wu Y, Feng J, Robbins TW, Xiao X. From chronic pain to depression: Neurogenesis-driven microglial remodeling in the hippocampal dentate gyrus. Science. 2026 Mar 19;391(6791):eaee6177. doi: 10.1126/science.aee6177. Epub 2026 Mar 19. PubMed 41855330 ↗
  • Wang D, Du Z, Wen X, Li Q, Liu Y, Tang J, Shui C, Yu P, Yang L, Tu P, Liu X, Yuan C, Yu D, Ma T, Yuan K. Hippocampal transcranial temporal interference stimulation reduced craving in methamphetamine use disorder. Addict Behav. 2026 Mar;174:108581. doi: 10.1016/j.addbeh.2025.108581. Epub 2025 Dec 11. PubMed 41389502 ↗
  • Beanato E, Moon HJ, Windel F, Vassiliadis P, Wessel MJ, Popa T, Pauline M, Neufeld E, De Falco E, Gauthier B, Steiner M, Blanke O, Hummel FC. Noninvasive modulation of the hippocampal-entorhinal complex during spatial navigation in humans. Sci Adv. 2024 Nov;10(44):eado4103. doi: 10.1126/sciadv.ado4103. Epub 2024 Oct 30. PubMed 39475597 ↗
  • Lamos M, Bockova M, Missey F, Lubrano C, de Araujo E Silva M, Trajlinek J, Studnicka O, Daniel P, Carron R, Jirsa V, Chrastina J, Jancalek R, Glowacki ED, Cassara A, Neufeld E, Rektorova I, Williamson A. Noninvasive Temporal Interference Stimulation of the Subthalamic Nucleus in Parkinson's Disease Reduces Beta Activity. Mov Disord. 2025 Jun;40(6):1051-1060. doi: 10.1002/mds.30134. Epub 2025 Apr 9. PubMed 40202094 ↗
  • Vassiliadis P, Beanato E, Popa T, Windel F, Morishita T, Neufeld E, Duque J, Derosiere G, Wessel MJ, Hummel FC. Non-invasive stimulation of the human striatum disrupts reinforcement learning of motor skills. Nat Hum Behav. 2024 Aug;8(8):1581-1598. doi: 10.1038/s41562-024-01901-z. Epub 2024 May 29. PubMed 38811696 ↗
  • Ma R, Xia X, Zhang W, Lu Z, Wu Q, Cui J, Song H, Fan C, Chen X, Zha R, Wei J, Ji GJ, Wang X, Qiu B, Zhang X. High Gamma and Beta Temporal Interference Stimulation in the Human Motor Cortex Improves Motor Functions. Front Neurosci. 2022 Jan 3;15:800436. doi: 10.3389/fnins.2021.800436. eCollection 2021. PubMed 35046771 ↗
  • Demchenko I, Tailor I, Chegini S, Yu H, Gholamali Nezhad F, Rueda A, Kever A, Krishnan S, Datta A, Meltzer JA, Graham SJ, Schweizer TA, Rampersad S, Boyden ES, Violante IR, Chen R, Lozano AM, Bhat V. Human Applications of Transcranial Temporal Interference Stimulation: A Systematic Review. medRxiv [Preprint]. 2025 Sep 23:2025.05.16.25327804. doi: 10.1101/2025.05.16.25327804. PubMed 40463528 ↗
  • Rampersad S, Roig-Solvas B, Yarossi M, Kulkarni PP, Santarnecchi E, Dorval AD, Brooks DH. Prospects for transcranial temporal interference stimulation in humans: A computational study. Neuroimage. 2019 Nov 15;202:116124. doi: 10.1016/j.neuroimage.2019.116124. Epub 2019 Aug 29. PubMed 31473351 ↗
  • Vachon-Presseau E, Roy M, Martel MO, Caron E, Marin MF, Chen J, Albouy G, Plante I, Sullivan MJ, Lupien SJ, Rainville P. The stress model of chronic pain: evidence from basal cortisol and hippocampal structure and function in humans. Brain. 2013 Mar;136(Pt 3):815-27. doi: 10.1093/brain/aws371. PubMed 23436504 ↗
  • Duric V, McCarson KE. Persistent pain produces stress-like alterations in hippocampal neurogenesis and gene expression. J Pain. 2006 Aug;7(8):544-55. doi: 10.1016/j.jpain.2006.01.458. PubMed 16885011 ↗
  • Zhang J, Zheng X, Zhang G, Cheng Z, Liu Y, Zhang L, Zhang J, Liu X, Yang Z. Chronic postoperative pain induces contextual fear extinction dysfunction through hippocampal NMDAR/BDNF/TrkB signaling pathway in mice. Transl Psychiatry. 2025 Jun 17;15(1):203. doi: 10.1038/s41398-025-03417-0. PubMed 40527933 ↗
  • Perry Caleb, Heathcote Lauren, Thomas Kayla, et al. The role of hippocampus and amygdala morphology in memory bias of learned fear in youth with chronic pain[J]. The Journal of Pain, 2021, 22(5): 604.
  • Berger SE, Vachon-Presseau E, Abdullah TB, Baria AT, Schnitzer TJ, Apkarian AV. Hippocampal morphology mediates biased memories of chronic pain. Neuroimage. 2018 Feb 1;166:86-98. doi: 10.1016/j.neuroimage.2017.10.030. Epub 2017 Nov 6. PubMed 29080714 ↗
  • Gartner KE, Rustioni S, Vohra A, Almosawi M, Hill N, Stewart T, van Wouwe NC, Zemmar A. A comprehensive review of the supraspinal mechanisms of spinal cord stimulation on chronic pain and cognition. Front Pain Res (Lausanne). 2025 Jul 28;6:1589723. doi: 10.3389/fpain.2025.1589723. eCollection 2025. PubMed 40792126 ↗
  • Yang S, Chang MC. Chronic Pain: Structural and Functional Changes in Brain Structures and Associated Negative Affective States. Int J Mol Sci. 2019 Jun 26;20(13):3130. doi: 10.3390/ijms20133130. PubMed 31248061 ↗
  • Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011 Mar;152(3 Suppl):S2-S15. doi: 10.1016/j.pain.2010.09.030. Epub 2010 Oct 18. PubMed 20961685 ↗
  • Coelho ACS, Dourado JF, Lima POP. High-intensity and low-intensity Pilates have similar effects on pain and disability in people with chronic non-specific low back pain: a randomised trial. J Physiother. 2025 Apr;71(2):100-107. doi: 10.1016/j.jphys.2025.03.002. Epub 2025 Mar 22. PubMed 40122758 ↗
  • Deyo RA, Weinstein JN. Low back pain. N Engl J Med. 2001 Feb 1;344(5):363-70. doi: 10.1056/NEJM200102013440508. No abstract available. PubMed 11172169 ↗
  • Hartvigsen J, Hancock MJ, Kongsted A, Louw Q, Ferreira ML, Genevay S, Hoy D, Karppinen J, Pransky G, Sieper J, Smeets RJ, Underwood M; Lancet Low Back Pain Series Working Group. What low back pain is and why we need to pay attention. Lancet. 2018 Jun 9;391(10137):2356-2367. doi: 10.1016/S0140-6736(18)30480-X. Epub 2018 Mar 21. PubMed 29573870 ↗
  • GBD 2021 Low Back Pain Collaborators. Global, regional, and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023 May 22;5(6):e316-e329. doi: 10.1016/S2665-9913(23)00098-X. eCollection 2023 Jun. PubMed 37273833 ↗
  • Onuora S. Low back pain is a growing concern. Nat Rev Rheumatol. 2023 Aug;19(8):462. doi: 10.1038/s41584-023-00999-1. No abstract available. PubMed 37430106 ↗
  • Trolle N, Maribo T, Jensen LD, Christiansen DH. Task-Specific Sensitivity in Physical Function Testing Predicts Outcome in Patients With Low Back Pain. J Orthop Sports Phys Ther. 2020 Apr;50(4):206-213. doi: 10.2519/jospt.2020.8953. Epub 2019 Oct 30. PubMed 31663814 ↗
  • Grossman N, Bono D, Dedic N, Kodandaramaiah SB, Rudenko A, Suk HJ, Cassara AM, Neufeld E, Kuster N, Tsai LH, Pascual-Leone A, Boyden ES. Noninvasive Deep Brain Stimulation via Temporally Interfering Electric Fields. Cell. 2017 Jun 1;169(6):1029-1041.e16. doi: 10.1016/j.cell.2017.05.024. PubMed 28575667 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Sep 2029, 38 months after the start.

Of 1,295 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 38 months is above that.

Counting every sponsor, half of 1,378 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Sep 21, 2026
StartActual
Jul 3, 2026
Primary completionEst.
Sep 24, 2029
CompletionEst.
Sep 24, 2029
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07832188
Responsible party
Sponsor
First posted
Sep 21, 2026
Start date
Jul 3, 2026
Primary completion
Sep 24, 2029 (estimated)
Completion
Sep 24, 2029 (estimated)
Last update
Sep 21, 2026

Study contacts

Xiaofei Zhang
Contact
xfeizhang2025@163.com
86-15563139097

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion